Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
Peñarrubia MJ, Odriozola J, González C, Massagué I, Miguel A, González San Miguel JD, Pérez Encinas M, Lavilla E, Giraldo MP, Casado LF, Ferrer S, Steegmann JL; Spanish Group on IFN and CML. Peñarrubia MJ, et al. Among authors: massague i. Ann Hematol. 2003 Dec;82(12):750-8. doi: 10.1007/s00277-003-0724-z. Epub 2003 Sep 27. Ann Hematol. 2003. PMID: 14517691 Clinical Trial.
Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J, Ferro MT, Benítez E, Pérez-Pons C, Giralt M, Escribano L, Lavilla E, Miguel A, Areal C, Pérez-Encinas M, Abad A, Maldonado J, Massagué I, Fernández-Rañada JM. Steegmann JL, et al. Among authors: massague i. Haematologica. 1999 Nov;84(11):978-87. Haematologica. 1999. PMID: 10553157 Clinical Trial.
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF, García-Gutiérrez JV, Massagué I, Giraldo P, Pérez-Encinas M, de Paz R, Martínez-López J, Bautista G, Osorio S, Requena MJ, Palomera L, Peñarrubia MJ, Calle C, Hernández-Rivas JÁ, Burgaleta C, Maestro B, García-Ormeña N, Steegmann JL. Casado LF, et al. Among authors: massague i. Cancer Med. 2015 Jul;4(7):995-1002. doi: 10.1002/cam4.440. Epub 2015 Mar 10. Cancer Med. 2015. PMID: 25756742 Free PMC article.
[Infection in the neutropenic patient].
López A, Estíbalez A, Bueno J, Juliá A, Zuazu J, Massagué I. López A, et al. Among authors: massague i. Enferm Infecc Microbiol Clin. 1989;7 Suppl 1:34-40. Enferm Infecc Microbiol Clin. 1989. PMID: 2518770 Review. Spanish. No abstract available.
[Intestinal mucormycosis in acute leukemia].
López A, Juliá A, Bueno J, Zuazu J, Estíbalez A, Massagué I, Allende E. López A, et al. Among authors: massague i. Med Clin (Barc). 1988 Nov 26;91(18):704-6. Med Clin (Barc). 1988. PMID: 3230990 Spanish. No abstract available.
[Infection by fungi in granulopenic patients].
Bueno J, López A, Estíbalez A, Juliá A, Massagué I, Zuazu J, Acebedo G. Bueno J, et al. Among authors: massague i. Sangre (Barc). 1988 Oct;33(5):341-6. Sangre (Barc). 1988. PMID: 3073533 Review. Spanish. No abstract available.
11 results